Table 3 shows the result of multivariate regression analysis for PFS and OS using a Cox proportional hazards model including CTCBL, age at study entry, number of metastatic sites, site of metastasis, line of therapy, and molecular subtypes.
For PFS, only estrogen receptor, number of metastatic sites, and line of therapy were independent factors.
The prognostic factors with the most consistently demonstrated associations with outcomes were PS, number or site of metastases, previous therapy, smoking status, and HRQoL.
The prognostic factors with the most consistently demonstrated associations with outcomes were performance status, number or site of metastases, previous therapy, smoking status, and health-related quality of life.
This literature review identified several factors, including PS, number or site of metastases, previous therapy, smoking status, and HRQoL, that may account for HTE and outcomes in advanced NSCLC.
I think that in a way I would see DDP as the obvious first step kind of approach and it might be that through a period of skilling up the foster carers, and helping the child communicate some of these core difficulties and reasons why they are finding it so hard to be with these carers, that would open up the possibility of accessing other sorts of therapy (Site A).
Baseline data collection included patient demographic information, performance status, biochemistry, number and site of metastases, prior therapies, and duration of prior trastuzumab.
KRAS mutation was not associated with multiple metastatic sites at the time of therapy initiation.
Therefore non-invasive and tomographic imaging of surface expressed PS has gained interest not only in basic and translational research but also in various clinical disciplines to support diagnosis, localize pathological sites and assess efficacy of therapy.
Presence of multiple metastatic sites at the time of therapy initiation was the risk factor for early progression (HR = 1.51; p < 0.001) and this risk was higher in patients with KRAS mutation (HR = 1.77; 95% CI 1.43 - 2.18) compared to patients with wtKRAS (HR = 1.37; 95% CI 1.16 - 1.62).
